

Title (en)

Herpes Simplex Virus for the treatment of liver cancer

Title (de)

Herpes Simplex Virus zur Behandlung von Leberkrebs

Title (fr)

Virus de l'herpès simplex pour le traitement du cancer du foie

Publication

EP 2662117 A1 20131113 (EN)

Application

EP 12167750 A 20120511

Priority

EP 12167750 A 20120511

Abstract (en)

An oncolytic herpes simplex virus is disclosed for use in a method of treating primary liver cancer.

IPC 8 full level

A61P 35/00 (2006.01); **A61K 31/4412** (2006.01); **A61K 31/704** (2006.01); **A61K 35/66** (2015.01); **A61K 35/76** (2006.01); **A61K 35/763** (2015.01)

CPC (source: EP GB US)

A61K 31/44 (2013.01 - EP US); **A61K 31/4412** (2013.01 - EP GB US); **A61K 31/704** (2013.01 - EP GB US); **A61K 35/66** (2013.01 - EP US); **A61K 35/763** (2013.01 - EP GB US); **A61P 35/00** (2017.12 - EP); **A61K 2300/00** (2013.01 - EP US)

C-Set (source: EP US)

1. **A61K 35/763 + A61K 2300/00**
2. **A61K 31/44 + A61K 2300/00**
3. **A61K 31/76 + A61K 2300/00**
4. **A61K 31/4412 + A61K 2300/00**

Citation (applicant)

- EP 0571410 A1 19931201 - SMITHKLINE BEECHAM BIOLOG [BE]
- WO 9213943 A1 19920820 - SMITHKLINE BEECHAM BIOLOG [BE]
- WO 2005049846 A2 20050602 - BROWN SUSANNE MOIRA [GB], et al
- WO 2005049845 A2 20050602 - CRUSADE LAB LTD [GB], et al
- WO 03068809 A2 20030821 - CRUSADE LAB LTD [GB], et al
- BRUIX ET AL., J HEPATOL, vol. 35, 2001, pages 421 - 30
- BELL, J.: "Oncolytic Viruses: An Approved Product on the Horizon?", MOL THER., vol. 18, no. 2, 2010, pages 233 - 234, XP055164263, DOI: doi:10.1038/mt.2009.314
- KELLY ET AL., EXPERT OPIN INVESTIG DRUGS, vol. 17, no. 7, July 2008 (2008-07-01), pages 1105 - 1113
- GEEVARGHESE ET AL., HUMAN GENE THERAPY, vol. 21, September 2010 (2010-09-01), pages 1119 - 1128
- MEIGNIER B; ROIZMAN B: "Herpes simplex virus vaccines", ANTIVIRAL RES., vol. 1, 1985, pages 259 - 265
- MEIGNIER B; LONGNECKER R; ROIZMAN B: "In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents", J INFECT DIS., vol. 158, no. 3, 1988, pages 602 - 614
- WONG R J; KIM S H; JOE J K ET AL.: "Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus", J AM COLL SURG., vol. 193, no. 1, 2001, pages 12 - 21
- MOLECULAR THERAPY, vol. 18, no. 2, February 2010 (2010-02-01), pages 233 - 234
- CHOU; ROIZMAN, PROC. NATL. ACAD. SCI., vol. 89, April 1992 (1992-04-01), pages 3266 - 3270
- TODA ET AL., HUMAN GENE THERAPY, vol. 9, 10 October 1995 (1995-10-10), pages 2177 - 2185
- GEEVARGHESE ET AL., HUMAN GENE THERAPY, vol. 21, no. 9, September 2010 (2010-09-01), pages 1119 - 28
- THOMPSON ET AL., VIROLOGY, vol. 131, 1983, pages 171 - 179
- SIMPSON ET AL., CANCER RES 2006, vol. 66, no. 9, 1 May 2006 (2006-05-01), pages 4835 - 4842
- LIU ET AL., GENE THERAPY, vol. 10, 2003, pages 292 - 303
- BROWN ET AL., JOURNAL OF GENERAL VIROLOGY, vol. 75, 1994, pages 2367 - 2377
- MACLEAN ET AL., JOURNAL OF GENERAL VIROLOGY, vol. 72, 1991, pages 631 - 639
- "Remington's Pharmaceutical Sciences, 20th Edition," 2000, LIPPINCOTT, WILLIAMS & WILKINS
- BERGE ET AL.: "Pharmaceutically Acceptable Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
- VECCHI ET AL., HEPATOLOGY, vol. 51, no. 2, February 2010 (2010-02-01), pages 654 - 9

Citation (search report)

- [X1] WO 2007026146 A1 20070308 - CRUSADE LAB LTD [GB], et al
- [X1] US 2010272691 A1 20101028 - CONNER JOE [GB]
- [XY1] LAM PAULA Y P ET AL: "An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 15, no. 6, 1 June 2007 (2007-06-01), pages 1129 - 1136, XP002606531, ISSN: 1525-0016
- [I] REINBLATT ET AL: "Herpes Viral Oncolysis: A Novel Cancer Therapy", JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, COLLEGE, CHICAGO, IL, US, vol. 205, no. 4, 1 October 2007 (2007-10-01), pages S69 - S75, XP022283650, ISSN: 1072-7515, DOI: 10.1016/J.JAMCOLLSURG.2007.06.333
- [I] HAWKINS L K ET AL: "Oncolytic biotherapy: a novel therapeutic platform", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 3, no. 1, 1 January 2002 (2002-01-01), pages 17 - 26, XP004811728, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(01)00618-0
- [IY] TOMOKI TODO: "Oncolytic virus therapy using genetically engineered herpes simplex viruses", FRONTIERS IN BIOSCIENCE, vol. 13, no. 13, 1 September 2002 (2002-09-01), pages 2060 - 159, XP055009778, ISSN: 1093-9946, DOI: 10.2741/2823
- [Y] WONG R J ET AL: "Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 13, 1 July 2002 (2002-07-01), pages 1213 - 1223, XP002971610, ISSN: 1043-0342, DOI: 10.1089/104303402320138998
- [Y] BROWN C W ET AL: "Oncolytic Viruses: A New Weapon to Fight Cancer", JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 39, no. 3, 1 September 2008 (2008-09-01), pages 115 - 127, XP025350702, ISSN: 1939-8654, [retrieved on 20080907]

- [Y] RAFAELA ARGNANI ET AL: "Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer", LIVER INTERNATIONAL, vol. 31, no. 10, 1 November 2011 (2011-11-01), pages 1542 - 1553, XP055037786, ISSN: 1478-3223, DOI: 10.1111/j.1478-3231.2011.02628.x
- [Y] VARGHESE SUSAN ET AL: "Oncolytic herpes simplex virus vectors for cancer virotherapy", CANCER GENE THERAPY, NORWALK, CT, US, vol. 9, no. 12, 1 December 2002 (2002-12-01), pages 967 - 978, XP002313119, ISSN: 0929-1903, DOI: 10.1038/SJ.CGT.7700537
- [Y] LI Y ET AL: "A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 61, no. 17, 1 January 2001 (2001-01-01), pages 6428 - 6436, XP002194693, ISSN: 0008-5472
- [Y] FALKSON ET AL: "Chemotherapy Studies in Primary Liver Cancer: A Prospective Randomized Clinical Trial", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 42, no. 5, 1 November 1978 (1978-11-01), pages 2149 - 2156, XP002120029, ISSN: 0008-543X
- [Y] BRUIX J ET AL: "67 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBANALYSIS OF SHARP TRIAL BASED ON BARCELONA CLINIC LIVER CANCER (BCLC) STAGE", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 50, 1 April 2009 (2009-04-01), pages S28 - S29, XP026495680, ISSN: 0168-8278, [retrieved on 20090401], DOI: 10.1016/S0168-8278(09)60069-6

Cited by

GB2516521A; GB2516521B; WO2018075447A1; WO2020109389A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

EP 2662117 A1 20131113; EP 2849852 A1 20150325; EP 2849852 B1 20190918; GB 201308445 D0 20130619; GB 2501991 A 20131113; US 2015125425 A1 20150507; WO 2013167909 A1 20131114

DOCDB simple family (application)

EP 12167750 A 20120511; EP 13724345 A 20130510; GB 2013051217 W 20130510; GB 201308445 A 20130510; US 201314400212 A 20130510